Now a team of researchers from Meenakshi Medical College Hospital and Research Institute in Tamil Nadu, India, has published a formal commentary in the same journal challenging that interpretation. In a Matters Arising contribution, R. Saravanan, Paramanantham Madhavan, R. Sivayogana, and K. Anusha do not dispute the value of the underlying registry analysis, which they describe as an important framework for evaluating rare cancers using population-level data. Instead, they raise two methodological concerns that, if correct, could substantially alter how the German findings should be read. The first concerns whether the apparent rise in multivisceral resection reflects a real change in surgical practice or simply an improvement in how operations were documented and coded over time. The second concerns the handling of missing data on tumor grade and metastatic status, variables that were absent in a large fraction of cases yet still used to stratify survival analyses. Both concerns strike at the heart of a growing movement in oncology: the use of registry data to draw clinical conclusions about diseases too rare for randomized trials.

The argument about coding is technically subtle but conceptually compelling. The German analysis of organ resections relied on a subset of only 1,318 patients with codeable resection procedures, a considerably smaller group than the full surgical cohort, and it depended entirely on whether the Operationen- und Prozedurenschlüssel, the German procedure coding system, captured a code for every organ removed during each operation. The commentary points out that the original paper itself acknowledged a parallel phenomenon: the rise in annual case numbers over the same period was attributed to improving case ascertainment and documentation completeness following the 2014 legal framework for cancer registration, not to a true increase in disease incidence. If overall case documentation improved across two decades, the Indian authors argue, it is plausible and untested that procedure-level documentation improved as well. Under that scenario, earlier multivisceral resections may have been underdocumented, with only the single most prominent procedure code recorded, while later cases benefited from more complete coding that captured every organ removed in the same operation. Part or all of the observed temporal trend would then reflect better paperwork rather than bolder surgery.

The distinction is far more than methodological tidiness. If the trend is substantially a documentation artifact, the commentary notes, then the implicit message to clinicians and registry stewards, that German surgical practice has progressively converged on international multivisceral resection guidelines for liposarcoma, would be overstated. The more accurate takeaway would concern the maturation of registry coding rather than the maturation of surgical decision-making. The authors propose a concrete diagnostic test: reporting the proportion of surgical cases with at least one codeable resection procedure by diagnosis year, alongside the existing organ-count trend, would allow readers to judge whether the apparent rise in multivisceral resection tracks improving procedure documentation or represents an independent change in clinical practice. If the two curves move together, the documentation explanation gains weight; if they diverge, the practice-change interpretation becomes more credible. Such a check costs nothing beyond additional analysis of data already in hand, which is precisely why the commentary frames its absence as a missed opportunity.

The second major concern involves missing data in the survival analyses. According to the commentary, grading information was missing in twenty-four percent of cases, and distant metastasis status was missing in fifty-five percent, yet both variables were used to stratify the survival analyses and the primary treatment description without any sensitivity analysis addressing whether the missingness was informative. This matters because of a well-known statistical hazard: complete-case analysis, in which patients lacking a given variable are simply excluded, produces unbiased results only if the missing data occur randomly. If, as the original paper’s own discussion suggests, earlier-era cases suffered from less complete documentation, then those cases may be disproportionately represented among patients with missing grading or staging information. The Kaplan-Meier survival curves and treatment-pattern tables restricted to complete cases would then systematically overrepresent more recent, better-documented tumors, which may differ from the excluded cases in surgical approach, tumor biology ascertainment, or case mix. The resulting curves could paint a rosier or otherwise distorted picture of outcomes across the full registry cohort.

The commentary applies this concern specifically to the Kaplan-Meier estimates stratified by grade, which were calculated only among the roughly three-quarters of cases with recorded grading. No comparison of baseline characteristics between graded and ungraded cases was provided to establish that the two groups were otherwise similar. The authors suggest a remedy that mirrors their proposal on procedure coding: reporting whether missingness in grading and metastasis status varies systematically by diagnosis year, and providing a basic comparison of age, sex, and histology distribution between complete and incomplete cases. Such comparisons would allow readers to judge whether the survival and treatment-pattern findings generalize to the full registry cohort or are specific to the more thoroughly documented subset. The commentary also notes an internal inconsistency in the original paper’s logic: the study elsewhere treats improving documentation completeness as a plausible explanation for other temporal patterns in the dataset, yet does not extend that same reasoning to the grading and staging variables underlying the survival analysis.

What makes this exchange notable is its constructive tone and its broader relevance. The Indian authors explicitly state that neither concern displaces the substantial contribution of the German study, which established a reproducible, histology- and location-specific framework for extracting a rare tumor cohort from national registry data. They call that framework a genuinely useful methodological template for future rare-cancer registry research well beyond retroperitoneal sarcoma. The stakes they identify are correspondingly high: distinguishing genuine practice change from improved documentation completeness, and characterizing whether missing data correlate with diagnosis era, would allow clinicians and health-policy readers to rely on reported trends as evidence of evolving surgical practice with greater confidence, rather than treating documentation artifacts as clinical signals. In an era when health systems increasingly mine administrative and registry data to guide cancer care, the commentary is a reminder that the quality of the data pipeline can be as consequential as the quality of the medicine it records.

The technical issues at play are familiar to epidemiologists but deserve wider understanding. Procedure coding systems like the German OPS are designed for billing and administration, not research, and their granularity depends on local coding habits, staffing, and evolving regulations. Studies of complex surgical specimens in other fields have documented substantial variability in how thoroughly multi-organ procedures are captured in coded records, and the commentary cites work on procedural terminology optimization in genitourinary surgery as an illustration. Similarly, the problem of informative missingness in registry-based survival analysis has prompted a growing literature on imputation techniques for Kaplan-Meier estimation, which the commentary references. Neither problem is unique to the German study; both are endemic to registry research. The commentary’s contribution is to show how these general hazards map onto the specific claims of a high-profile national analysis, and to propose analyses that would resolve the ambiguity without requiring new data collection.

For patients with retroperitoneal sarcoma, the practical implications are indirect but real. Multivisceral resection is the single most important determinant of long-term survival in this disease, and international guidelines recommend aggressive compartmental surgery for liposarcoma whenever feasible. If German practice has genuinely converged on those guidelines over two decades, that is encouraging news for the roughly one in a hundred thousand people diagnosed each year. If instead the trend partly reflects coding maturation, the appropriate response is not complacency about surgery but investment in registry quality, so that future analyses can distinguish the two. The commentary, published open access in October 2026, ultimately asks for methodological consistency: the same skepticism about documentation quality that the original authors applied to case counts should be applied to procedure codes, tumor grades, and staging data. Whether the German group responds with the requested sensitivity analyses will determine how confidently the oncology community can cite this study as evidence that surgical practice, and not merely surgical record-keeping, has changed.

Subject of Research: Methodological evaluation of German cancer registry data on retroperitoneal sarcoma treatment trends

Article Title: Comment on “Treatment of retroperitoneal sarcoma in Germany between 2000 and 2022: a retrospective analysis from the German Cancer Registry Group”

Article References: Comment on “Treatment of retroperitoneal sarcoma in Germany between 2000 and 2022: a retrospective analysis from the German Cancer Registry Group”. (n.d.). https://doi.org/10.1007/s00432-026-06591-w

Image Credits: AI Generated

DOI: 10.1007/s00432-026-06591-w

Keywords: retroperitoneal sarcoma, cancer registry, multivisceral resection, registry completeness, missing data, survival analysis, surgical oncology, liposarcoma, rare cancers, clinical epidemiology, procedure coding, Germany

Researchers led by Enlong Zhang and Yuan Li of Peking University Third Hospital, together with colleagues at Tsinghua University Hospital and Peking University International Hospital, developed a tumor habitat-based radiomics approach to distinguish retroperitoneal non-fatty dedifferentiated liposarcoma from leiomyosarcoma. Their retrospective study included 166 patients, 102 with dedifferentiated liposarcoma and 64 with leiomyosarcoma, all of whom underwent multiphase contrast-enhanced CT. Rather than treating each tumor as a single uniform blob, the team borrowed a concept from oncology known as intratumoral heterogeneity, the recognition that a cancer is a patchwork of biologically distinct microenvironments, each with its own cellularity, vascularity, necrosis, and stromal composition.

The technical core of the method is elegantly simple. On the largest axial slice of each tumor, the researchers applied a Simple Linear Iterative Clustering algorithm, a superpixel segmentation technique originally developed for computer vision, to divide the tumor image into hundreds of small, coherent regions of similar pixel intensity. A K-means clustering step then grouped these superpixels into three habitat subregions, effectively partitioning each tumor into three zones that reflect different levels of attenuation, a radiological proxy for tissue density. The team designated these subregions ROI1, ROI2, and ROI3, with ROI2 corresponding to the intermediate-attenuation zone that often represents a transitional territory between viable cellular tissue and degenerative change.

From each habitat subregion, across three imaging phases, the non-contrast phase, the arterial phase, and the venous phase, the researchers extracted a comprehensive panel of quantitative radiomics features. These included shape descriptors such as major axis length, first-order statistics capturing the distribution of gray values, and higher-order texture features derived from gray-level co-occurrence matrices, run-length matrices, size zone matrices, dependence matrices, and neighborhood gray-tone difference matrices, as well as wavelet-transformed versions of these features that probe texture at multiple spatial scales. Feature selection was performed independently within each subregion using LASSO regression, and predictive models were then built with XGBoost, a gradient-boosted decision tree algorithm renowned for its performance on tabular biomedical data.

The results point to a clear conclusion: contrast matters. Habitat radiomics models derived from contrast-enhanced CT generally outperformed those built on non-contrast images, suggesting that the way tumor subregions take up iodinated contrast, and therefore their vascular perfusion characteristics, carries diagnostic information that plain density measurements miss. The single best-performing model was built from the venous-phase intermediate-attenuation subregion, VP-ROI2. In the testing cohort it achieved an area under the receiver operating characteristic curve of 0.834, with a 95 percent confidence interval of 0.713 to 0.950, alongside an accuracy of 0.820, a sensitivity of 0.871, and a specificity of 0.737.

The venous-phase advantage is physiologically plausible. The venous phase of a contrast-enhanced CT, typically acquired around sixty to ninety seconds after injection, captures the period of maximum enhancement in many soft-tissue tumors, when contrast has diffused into the extracellular space and reflects capillary permeability and interstitial volume. Dedifferentiated liposarcoma and leiomyosarcoma differ in their microvascular architecture and stromal composition, and those differences apparently imprint distinguishable enhancement patterns on the intermediate-attenuation habitat. Interestingly, VP-ROI2 showed only a nominally significant advantage over its non-contrast counterpart, NP-ROI2, with a P value of 0.048 that fell to an adjusted P value of 0.173 after false discovery rate correction, a statistical caution the authors appropriately acknowledge. ROI2 nevertheless emerged as the most discriminative subregion on both arterial and venous phases.

Perhaps the most compelling aspect of the study is its commitment to interpretability, a virtue not always found in machine learning medicine. Using SHAP, or SHapley Additive exPlanations, a game-theoretic framework that quantifies each feature’s contribution to individual predictions, the team identified original_shape_MajorAxisLength and wavelet-based texture features as the most influential predictors. Shape matters, which makes intuitive sense: dedifferentiated liposarcomas and leiomyosarcomas differ in their growth patterns and margins. But the prominence of wavelet texture features, which encode fine-scale spatial patterning of pixel intensities, indicates that the microscopic organization of tumor tissue, its heterogeneity at radiologically invisible scales, is what truly separates the two diagnoses. The models were built and reported following established standards, including the Image Biomarker Standardization Initiative nomenclature and the TRIPOD guidelines for prediction model reporting, and the study received an assessment of radiomics quality.

The clinical implications are significant. Today, distinguishing these sarcomas preoperatively often depends on biopsy, and even then core needle sampling of a large heterogeneous tumor can miss the diagnostic territory, a problem known as sampling error. Accurate preoperative differentiation guides the surgical plan: dedifferentiated liposarcoma demands wide clearance of the fatty component along with the dedifferentiated nodule, whereas leiomyosarcoma management hinges more on vascular involvement and multimodal planning. A noninvasive imaging biomarker that can flag the likely diagnosis before the first incision could help surgeons counsel patients, select neoadjuvant strategies, and design clinical trials that stratify patients by histological subtype rather than by the blunt label of retroperitoneal sarcoma.

The authors are careful to frame this as a promising step rather than a finished clinical tool. The cohort was retrospective and drawn from Chinese hospitals, the tumors were segmented on the largest axial slice rather than in three dimensions, and the performance figures, while respectable, leave room for improvement before the model could stand beside pathology. External validation in independent, multiethnic cohorts and prospective testing will be essential before VP-ROI2-based habitat radiomics enters routine decision-making. Still, the study offers a vivid demonstration of a broader idea now sweeping through oncological imaging: that every tumor is a landscape of habitats, and that the map of that landscape, drawn automatically from a routine contrast-enhanced CT scan, may hold answers that biopsies, radiologists, and even pathologists struggle to provide. The venous phase, long treated as a routine addendum to the arterial spectacle, turns out to be where the sarcomas reveal their secrets.

Subject of Research: Venous-phase CT-based tumor habitat radiomics for differentiating retroperitoneal non-fatty dedifferentiated liposarcoma from leiomyosarcoma

Article Title: Venous-phase CT-based tumor habitat radiomics for differentiating retroperitoneal non-fatty dedifferentiated liposarcoma from leiomyosarcoma

Article References: Zhang, E., Li, Y., Ma, L., Ji, D., Zhang, M., & Lang, N. (2026). Venous-phase CT-based tumor habitat radiomics for differentiating retroperitoneal non-fatty dedifferentiated liposarcoma from leiomyosarcoma. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02784-4

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02784-4

Keywords: retroperitoneal sarcoma, dedifferentiated liposarcoma, leiomyosarcoma, radiomics, tumor habitat, intratumoral heterogeneity, computed tomography, machine learning, XGBoost, SHAP, cancer imaging, preoperative diagnosis